Log In
BCIQ
Print this Print this
 

ifabotuzumab (formerly KB004)

  Manage Alerts
Collapse Summary General Information
Company KaloBios Pharmaceuticals Inc.
DescriptionHumanized mAb targeting EPH receptor A3 (EPHA3) receptor tyrosine kinase developed using Humaneered technology
Molecular Target EPH receptor A3 (EPHA3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today